Background In the UK, needle and syringe programmes (NSP) are delivered via community pharmacies or substance misuse services (SMSNSP).
Introduction
In the UK, needle and syringe programmes (NSP) are largely delivered via substance misuse services (SMS) and by community pharmacies and aim to reduce blood-borne viral transmission. 1 -3 Provision of needles and syringes is free within UK-based NSP and return of used equipment encouraged. NSP provided by SMS (SMSNSP) may be done so alongside opiate substitution treatment, education and other therapeutic interventions and may operate at fixed sites and through mobile services. Pharmacy-based NSP may frequently be the site at which opiate substitution treatment is dispensed. Although generally not providing education or therapeutic interventions, pharmacy NSP may signpost individuals to SMS. In the UK, the provision of opiate substitution treatment to individuals within either SMS or community pharmacies should not be a barrier to the provision of clean injecting equipment. Other potential sources of needles and syringes include some accident and emergency departments, and rarely vending machines. In Wales, accessibility to NSP is influenced by geography; community pharmacies are widespread and found in many small centres of population, whereas SMSNSP tend to be located in larger population centres. There may be unequal distribution of NSP across the UK. 2 -4 A recent report of NSP provision in Scotland highlighted variation in the nature of provision with remote areas having more limited availability. 4 A similar review of NSP in England also reported variation in provision. 3 Qualitative research has highlighted the challenges of providing NSP, for example, concerns of public disclosure among injecting drug users (IDU) using pharmacy-based NSP. 5, 6 Evidence for the impact of NSP on hepatitis C (HCV) transmission is conflicting; however, there is evidence that NSP reduce risk and tentative evidence that NSP reduce HIV incidence. 7, 8 Interpreting data on NSP usage requires care; observational research may be subject to confounding and bias. For example, research from Vancouver highlighted differences in characteristics of those with or without access to NSP, with a higher HIV incidence among attendees. 9 In addition, there are likely to be differences in the design and nature of NSP both between and within different countries that reflect local logistical and political factors that must be considered when interpreting data. Nonetheless, there has been consistency in reported findings; research from Australia found similar demographic characteristics in pharmacy-based programmes and in specifically designed needle syringe programmes; however, risk behaviour across a number of domains was higher among attendees of the latter. 10 Likewise, research from Canada reported a lower risk profile among attendees of pharmacy-based NSP rather than attendees of fixed site and mobile NSP. 11 In the USA, research on the characteristics of first time NSP participants enrolling at either a mobile van-based site or a fixed pharmacy-based site reported differences in clientele; van-based enrolment was more common among frequent injectors; however, it was less common among African American participants. 12 In addition to NSP, individuals may obtain injecting equipment from other injectors, such secondary distribution has been associated with high-risk behaviours 13 but may reduce risk when compared with no NSP use. 14, 15 However, due to possible confounders (for example, the frequency of injecting and number of years injecting), the potential protective effect of NSP compared with the risks of secondary exchange may not be reflected in the observed blood-borne viral prevalence within these groups. Recent research from Australia highlighted reduced severe drug problems among individuals who did not attend NSP compared with NSP attendees 16 and, similar to the Vancouver findings, nonattendees reported lower markers of exposure to bloodborne viral infection. 9 Other Australian research reported similar needle sharing between pharmacy attendees and individuals relying on personal networks but different drug use patterns, with stimulant injection being more common among the latter group. 17 The research evidence suggests that there are thus differences in the risk profiles of individuals accessing different sources of clean needles and syringes. These differences may cover a wide range of variables and include drug type, ethnicity, levels of drug injecting, housing status and sexuality, all of which may be important in informing NSP design in the local context. This study examines the patterns of NSP use within Wales (UK) that, in contrast to some countries, 18 adopts a non-restrictive syringe dispensation policy and considers the implications of the findings for service delivery.
Methods
Seven hundred current or recent drug injectors (IDU) were opportunistically recruited from treatment services, NSP, hostels and the street in South Wales, UK, as part of a prospective cohort study of the incidence of blood-borne viruses described in more detail elsewhere. 19 Data presented here are from the baseline sampling interval of the study. Data collection occurred in towns and cities along the main transport links in South Wales (Newport and Caldicot, Cardiff and Barry, Bridgend, Neath and Porth Talbot, Swansea), the South Wales valleys (Merthyr Tydfil, Pontypridd, Rhydyfelin, Treorchy, Aberdare) and one outlying market town (Abergavenny). Recruitment was primarily by verbal signposting by drug workers, researchers and by interviewees themselves. Interviewees were paid a small sum (Ten pounds sterling) for their involvement. The target eligibility criteria were being a current or recent drug injector. Response rates were not systematically recorded; the nature of the opportunistic recruitment meant that many respondents self-referred themselves to interview sites and to interviewers. Dried blood spot samples and self-reported behavioural data were collected using a structured questionnaire. The questionnaire was administered by researchers. Blood samples were tested for HCV antibody and hepatitis B (HBV) antibody (anti-HBcore) using established methods. 20 In the data analysis, individuals were grouped by their main source of injecting equipment in the last 4 weeks; either pharmacy-based NSP, SMS-based NSP (SMSNSP) or needles and syringes obtained from other people termed 'secondary distribution' (e.g. partner, other IDU, drug dealer). This variable was obtained from a list of potential sources of clean needles and syringes of which respondents were asked to indicate the sources they had used in the last 4 weeks and which was their main source. Dummy variables were created by grouping the main source of needle and syringes into SMSNSP (drug agency site, mobile outlet, outreach worker), pharmacy NSP (freely distributed from a pharmacy, brought from a pharmacy) and secondary distribution (from partners, other IDU, drug dealer). Use of a different needle and syringe source in the last 4 weeks was grouped similarly. The communities from which individuals were recruited were grouped by population size (two large cities with populations of over 200 000 compared with all areas with ,200 000). Years injecting was estimated from age and year of first injection.
Where data were missing due to either no response to the question asked, or the interviewee refused to respond to the question asked, or responded that they did not know, then data was treated as missing (seen in tabulated data); data analysis was restricted to individuals with complete data, hence the denominator varied across different parts of the analysis. Where later or secondary questions informed or disagreed with the primary question asked, these latter responses were ignored. For example, whether the respondent had been tested for HCV was limited to individuals answering yes or no to a direct question, subsequent questions (year of test and test result) were ignored.
Homelessness and whether currently prescribed a substitute drug treatment regime in last 12 months were determined by direct questions. Ever having cleaned own needles and syringes and ever having been to prison were determined by direct questions. Injection site infection was estimated by any report of a range of infection symptoms in the last 12 months. Ever having injected crack cocaine was determined by a direct question and did not include responses to having injected crack in combination with heroin. Groin injection in the last 4 weeks was determined when respondents were asked to select from a list of possible injection sites (arms, legs, groin, other). Only individuals selecting at least one of the injection sites were included and non-responses were excluded.
Needle and syringe sharing in the last month was restricted to the answer from one question; 'in the last four weeks, from how many different people have you received used needles and syringes (including your partner)?'. We asked a range of additional questions addressing needle sharing; however, to avoid additional bias, these were not included in this analysis (as non-responders/not known were also treated as missing and not included). Paraphernalia sharing was estimated from any report of either front/back loading of a syringe from a used syringe, filter, spoon (or container) or washout water in the last 4 weeks, and respondents were asked whether events had 'never' occurred or occurred 'rarely', 'sometimes' or 'always' or 'don't know'. For both of these measures of injecting risk, either no response to the question or a 'don't know' response was treated as a missing value.
The proportion of IDU who collected sufficient needles and syringes to potentially have one clean needle/syringe available per injection were crudely estimated from frequency of injection and needle uptake. Self-reported injecting frequency was estimated from the number of days injected in the previous 4 weeks multiplied by approximate number of times injected on last full day. Needle and syringe uptake was estimated from the self-reported number of new needles and syringes obtained in the last week multiplied by four. If monthly estimated number of new needles and syringes collected exceeded the monthly estimate of injection frequency, then the individuals were assumed to have collected sufficient clean needles and syringes. Reports of number of needles and syringes given away or sold were ignored. The variable was considered only among individuals whose main source was either SMSNSP or pharmacy NSP.
An adjusted logistic regression analysis was carried out to examine associations between source of syringes and dependent variables. The model adjusted for region, age, gender, duration of injecting, homelessness and prison. We used the likelihood ratio test to test the strength of association between source of injecting equipment and the adjusted outcomes. The likelihood ratio test compared, for each dependent variable, adjusted models with and without source of injecting equipment. The study received ethical approval (MREC04/MRE09/21). Table 1 describes the characteristics of individuals accessing different sources of needles and syringes. Of the 700 individuals interviewed at baseline, 657 individuals provided information on their main source of equipment; 56% reported SMSNSP, 26% pharmacy NSP and 18% reported relying on secondary distribution. The average age of the sample was 29.6 years and 26% were female. In the large population region, a greater proportion of individuals utilized SMSNSP as their main source than in the smaller population region [62.5% (95% CI 57, 68) versus 51% (95% CI 46, 56)] and a smaller proportion used pharmacy NSP as their main source [20% (95% CI 15, 25) vs. 30% (95% CI 25, 35)]. Sixty-eight per cent of pharmacy NSP and 59% of SMSNSP attendees collected sufficient equipment to potentially cover their injecting needs.
Results
In the adjusted multivariate analysis, IDU attending SMSNSP as their main source were more likely to report homelessness, groin injection, having injected .16 days/month, they also had a higher prevalence of anti-HBcore than IDU primarily using pharmacy NSP (Table 2 ). In Table 2 , contrary to convention, the dependant variable in each model is described in the first column and varies by row. The denominator excluding missing values is shown for each variable. When comparing individuals whose main source was secondary distribution with those whose main source was SMSNSP, individuals were younger, had a lower prevalence of antibodies to HCV, were less likely to report homelessness, opiate substitution treatment or crack injection, to have injected 16 or more days/month, to have cleaned their own syringes, to have had injection site infections and more likely to report being recent onset injectors (injecting for less than 1 year) ( Table 2 ). The likelihood ratio test results confirmed the model fit for variables with significant associations with needle/syringe source [with the exception of anti-HBcore prevalence (P ¼ 0.065)].
Some respondents used more than one source of equipment and there was a crossover between the use of SMSNSP and pharmacy NSP when use in the last month was considered: of those whose main source was SMSNSP, 41% used only SMSNSP whereas 36% also used pharmacy NSP in the last month and 43% also used secondary distribution. Similarly, among those whose main source was pharmacy NSP, 42% used only pharmacy NSP whereas 33% also used SMSNSP and 42% also used secondary distribution in the last month. In contrast, among individuals primarily using 
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secondary distribution, 76% of respondents relied solely on secondary distribution in the previous month and only 16% used SMSNSP and 14% used pharmacy NSP in the previous month. To generate these proportions, non-responses to use of a particular source in the last 4 weeks were assumed to indicate non-use and as such were included in the denominators for each of the main sources.
Discussion
Main finding of this study
The data indicate that the different types of NSP provision are attracting a different profile of IDU and suggest that SMSNSP attract individuals vulnerable to infection as an elevated proportion report having been homeless and report an increased frequency of injection. These data do not imply any causal link between the use of NSP and viral prevalence; this picture is likely to be confounded by regional prevalence differences and, perhaps, a greater willingness among injectors with a longer period of risk exposure to use NSP. Despite a lower prevalence of antibodies to HCV among IDU whose primary source was secondary exchange, needle and syringe sharing was similar across groups accessing different needle and syringe sources. We suggest that a reduced period of exposure, both in terms of the number of years injected and the number of days injected per month, is likely to underlie this pattern of infection. In the regions with larger population centres, a greater proportion of individuals primarily utilize SMSNSP than in the area with smaller population centres. We assume that this reflects differences in the distribution of NSP type across regions. There is no evidence that being in substitution treatment is a deterrent to using SMSNSP. These data reveal an interesting crossover of use, with 40% of NSP users utilizing only their main source in the previous month, approximately one-third using the alternative NSP Analysis was adjusted for region, age group, gender, duration of injecting, homelessness and prison. Adjusting variables were excluded from models in which they were the dependent variable. The likelihood ratio test was used to compare a model for each dependent variable with and without source of injecting equipment included in the models. The dependent variable in each model is described in the first column and varies by row.
source in the previous month and over 40% obtaining needles and syringes from other individuals. Thus, exchange of needle and syringes between individuals, even among those utilizing NSP appears common. In contrast, individuals whose main source of needles and syringes was secondary distribution had a much lower crossover with only 16% using SMSNSP and 14% pharmacy NSP in the previous month, and approximately three-quarters using only secondary distribution. This finding adds to the picture of vulnerability to infection and isolation from potential health interventions experienced by this group. These data suggest that there is much to be gained by ensuring those individuals relying on secondary exchange are reached by the main pillars of risk reduction, namely opiate substitution treatment and NSP, at the earliest opportunity. We know little of the nature or extent of the transition from secondary distribution to use of NSP. If, as is suggested by this research, individuals relying on secondary distribution are at the start of an injecting career, then individuals who pick up equipment for their hidden contacts should be encouraged to signpost these individuals into services. In addition, outreach and peer education should be seriously considered to reach these individuals with poor service access. Despite the crude measure of needle and syringe coverage used in this study, the data suggest that even with 68% of SMSNSP whose uptake of needles and syringes is sufficient for their level of injecting, a large portion of IDU are collecting insufficient equipment. NSP should ensure that the provision of needles and syringes matches the needs of their clients.
What is already known on this topic
An association between NSP use and elevated viral prevalence has been previously described, notably in the findings of the Vancouver study. 9 Research from both Australia and Canada suggests that a different profile of IDU utilize pharmacy-based NSP than SMSNSP. 10, 11 The differences are to extent confounded by the drug use characteristics and demographic patterns of different countries; nonetheless, it is apparent that NSP located within SMS, or set up as fixed or mobile specialist services, are likely to be used by individuals whose risk behaviour and drug use-related problems are higher than those seen in pharmacy outlets. We observed an elevated proportion of individuals reporting homelessness among individuals whose primary source was SMSNSP; in the population studied in this research and elsewhere, HCV infection has been previously associated with homelessness. 19, 21 The study supports research indicating the vulnerability of individuals who primarily rely on secondary distribution to obtain clean injecting equipment. 13, 14, 16, 22, 23 Such individuals tend to be younger and with poor uptake of opiate substitution treatment; in addition, women may be at added risk through relying on their partners. 23 That this group had low markers of infection indicates that there is scope for prevention. It has been argued that secondary syringe distribution offers an opportunity for the dissemination of important prevention messages 13 with overlapping risk and benefits of secondary distribution participation. Higher syringe coverage has been associated with lower HIV risk 24 and an association between supply and syringe sharing has been previously described. 25, 26 Limitations of this study
We recognize limitations in the study design; the sample size of the study resulted in a loss of power to discriminate between marginal differences. The study used a non-probability sampling strategy; a pragmatic approach when sampling from a population of unknown structure. We can thus not be sure how representative our sample is of the whole population of IDU in Wales. We expect that it will over represent those whose drug use is more visible and are thus more willing to make public their drug use through study involvement. We did not carryout adjustment to control for the chance of finding a misclassified significant association when carrying out multiple tests; rather we considered the strengths of associations between dependent and independent variables in light of biological plausibility. In addition, these data are drawn from a country with a long history of NSP provision and where there are no significant legal or cultural barriers to provision; the findings may not be relevant in countries with more limited NSP availability. The crude measure of syringe coverage does not take into account the number of syringes given away, while this is likely to overestimate syringe coverage, it provides a measure of the potential each individual has to inject with clean equipment. The data contained a number of missing values which may have influenced outcomes.
What this study adds SMSNSP attract high-risk clients, particularly homeless IDU. It is important that SMSNSP maximize the opportunities to intervene to reduce risk behaviour and they are in a position to do so. Pharmacy NSP have a central role in providing clean injecting equipment; their availability in communities who do not have access to specialist SMS is of paramount importance. Both options are thus important components of integrated and comprehensive NSP.
IDU not utilizing NSP show a lower prevalence of HCV infection that is likely to reflect a younger age and reduced frequency of injecting; however, they have poor uptake of both opiate substitution treatment and HCV testing. Further research into the role of differing models of NSP should account for selection bias in recruitment and adjust for potential confounding.
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